Cuban lung cancer vaccine submitted in Serbia; U.K. may recommend AZ's FLUENZ for all children over 5;

> The Cuban lung cancer vaccine, Cimavax EGF, will be submitted for approval in Serbia in the fourth quarter of 2012 and could be available in 2013, under a collaboration between CIMAB (Cuban Center of Molecular Immunology of Havana) and the Serbian Torlak Institute. Article

> Differences in levels of T helper cells could explain why some people live longer with HIV and could be a new target for HIV vaccines. Press release

> The U.K. Joint Committee on Vaccination and Immunisation (JCVI) is considering recommending AstraZeneca's FLUENZ live attenuated flu vaccine to all children over age 5. Article

> Antibodies in breast milk could neutralize HIV; these may lead to a new route to HIV vaccination. Press release | Article

> Desentum, a Finnish VTT spinoff, is developing anti-allergy vaccines. Article

> Eurocine Vaccines is developing an experimental nasal pneumococcal vaccine, and this has protected mice against intranasal challenge, giving the same level of protection as a standard injected vaccine. Press release

> Researchers at the University of Adelaide are looking at new strategies to develop meningitis vaccines. Press release

> Advaxis has completed Phase II enrollment of its cervical cancer immunotherapy. Press release

And Finally… City of Hope has been given a $5 million grant to develop a T cell-based immunotherapy against glioma. Press release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.